CSL Breaks Ground on Illinois Plasma Therapy Expansion

CSL has broken ground on a $1.5 billion expansion of its manufacturing facility in Kankakee, Illinois. The project, announced March 9, is expected to create at least 300 new jobs while increasing production of plasma-derived therapies and albumin products. The expansion incorporates advanced manufacturing technologies designed to enhance efficiency and output. CEO and Managing Director Gordon Naylor said the investment supports the company’s mission to provide therapies that help patients manage serious medical conditions and improve quality of life.